We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





Sebia Showcases HbA1c Testing Solutions for Every Size Laboratory at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022

Sebia (Lisses, France) is showcasing its wide portfolio of instruments and tests designed to address clinical needs and improve laboratory efficiency and safety at the 2022 AACC Clinical Lab Expo. More...

From the lowest to the highest volumes, with standalone instruments to workcell configurations, Sebia will highlight various solutions for laboratories at the event.

At AACC 2022, Sebia is demonstrating the CAPILLARYS 3 TERA MC high throughput capillary electrophoresis system that allows the combination of one to three CAPILLARYS 3 TERA instruments to a Sebia loader, with a loading capacity of 528 samples in one row. This high volume workcell provides three hours autonomy on HbA1c, and hemoglobin testing, and more than two hours on proteins, processing up to 528 samples in one go. The system can be fed continuously with additional racks, and the reagent management system allows ad-hoc reagent addition at any time, without interruption. Sebia also highlighted its portfolio of tests from multiple myeloma to metabolic disorders, hemoglobinopathies and genetic diseases.

In addition, Sebia will showcase its fully automated, random access Alegria 2 ELISA platform with its comprehensive menu of antigen assays & panels utilizing a unique Monotest strip technology that allows serum, plasma, and fecal sample testing in the same run. Visitors to the company’s AACC 2022 booth can learn about Phoresis CORE, the unified software solution for labs utilizing Sebia instruments which offers traceable patient sampling from reagent to result, remote interpretation in real-time, from anywhere, and with comprehensive patient history for all of its assays. Visitors can also learn how labs can partner with the company for its Sebia Workflow Service to maximize automation, reduce errors, and improve workflow.
 

Related Links:
Sebia 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.